-+ 0.00%
-+ 0.00%
-+ 0.00%

Cyprumed's Oral Peptide Tablet Technology Enters Human Clinical Development As MSD Initiates Phase I Trial, Triggering Milestone Payment For Up To $493M From MSD

Benzinga·09/29/2026 08:48:17
Listen to the news
  • The Phase I clinical trial will evaluate a proprietary drug candidate formulated using Cyprumed’s oral tablet technology, marking the first Cyprumed technology program to enter human clinical development
  • The milestone triggers a payment to Cyprumed under the companies’ existing collaboration agreement